ClinicalTrials.gg
CompletedNCT04567303BURGUNDYUpdated Sep 14, 2026

Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration

A Phase 1/2 interventional study of Zifibancimig and Ranibizumab in Macular Degeneration, sponsored by Hoffmann-La Roche. Completed at 37 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
177
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Enrollment
36th of 124
177 · median 64
Started
2020
the only one that year
Phase 1/2
15 of 125
none open now
Registered
113th of 125
by date
Lead sponsor
5 of 125
Hoffmann-La Roche

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 36th largest by enrollment of the 124 interventional ones that give a count, is the only one that started in 2020, is one of 15 in phase 1/2, and was the 113th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the port delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD).

03

Conditions studied

  • Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Part 1, Part 2 and Part 3

Inclusion Criteria:

  • Willing to allow AH collection

Part 1 and Part 2

Ocular Inclusion Criteria for Study Eye:

  • Choroidal neovascularization (CNV) exclusively due to age-related macular degeneration (AMD)
  • Anti-vascular endothelial growth factor (VEGF) or anti-VEGF/Angiopoietin-2 (Ang-2) IVT treatment-naïve, or pre-treated with anti-VEGF or anti-VEGF/Ang-2 no less than two months prior to Day 1
  • Sufficiently clear ocular media and adequate pupillary dilatation to allow for analysis and grading by the central reading center of fundus photography (FP), fluorescein angiography (FA), fundus autofluorescence (FAF), and spectral domain optical coherence tomography (SD-OCT) images
  • Decreased BCVA attributable primarily to nAMD, with BCVA letter score of 78 to 34 letters (inclusive) on ETDRS-like charts at screening. In case both eyes of a participant are eligible, the eye with the lower BCVA score should become the study eye

Part 3

Ocular Inclusion Criteria for Study Eye:

  • CNV exclusively due to AMD
  • Diagnosis of nAMD within 36 months prior to the screening visit
  • Previous treatment with at least one IVT anti-VEGF or anti-VEGF/Ang-2 administrations IVT for nAMD. The last IVT administration must have occurred at least 21 days prior to the screening visit
  • Demonstrated response to prior IVT anti-VEGF or anti-VEGF/Ang-2 treatment since diagnosis
  • Availability of historical VA data prior to the first anti-VEGF or anti-VEGF/Ang-2 treatment for nAMD
  • Sufficiently clear ocular media and adequate pupillary dilatation to allow for analysis and grading
  • Decreased BCVA attributable primarily to nAMD with letter score of 78 to 34 letters (inclusive) or better on ETDRS-like charts

Ocular Exclusion Criteria for Study Eye:

  • History of vitrectomy surgery, submacular surgery, other intraocular surgery, or any planned surgical intervention during the study period
  • Cataract surgery without complications within three months preceding the screening visit or planned during the study period
  • Aphakia or absence of the posterior capsule. Previous violation of the posterior capsule is also an exclusion criterion, unless it occurred as a result of yttrium-aluminum garnet laser posterior capsulotomy in association with prior, posterior chamber intraocular lens implantation
  • Prior macular treatment with verteporfin, external beam radiation therapy, transpupillary thermotherapy, or any type of laser photocoagulation
  • Prior treatment with IVT or implant (e.g., triamcinolone, ozurdex, iluvien)
  • Subretinal hemorrhage >50% of the total lesion area and/or involving the fovea
  • Subfoveal fibrosis or subfoveal atrophy
  • Retinal pigment epithelial tear involving the macula
  • History of vitreous hemorrhage, rhegmatogenous retinal detachment, glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery, and corneal transplant
  • History of rhegmatogenous retinal tears or peripheral retinal breaks within three months prior to the screening visit
  • Actual or history of myopia >-8 diopters
  • Uncontrolled ocular hypertension or glaucoma (defined as intraocular pressure [IOP] >25 millimeters of mercury (mm Hg) or a cup to disc ratio >0.8, despite treatment with antiglaucoma medication) and any such condition the Investigator determines may require a glaucoma-filtering surgery during a participant's participation in the study
  • Concurrent intraocular conditions (e.g., cataract, diabetic retinopathy, epiretinal membrane with traction, macular hole) that, in the opinion of the Investigator, could either: require medical or surgical intervention during the study period to prevent or treat visual loss that might result from that condition; or likely contribute to loss of BCVA over the study period if allowed to progress untreated; or preclude any visual improvement due to substantial structural damage
  • Concurrent conjunctival, Tenon's capsule, and/or scleral condition in the supero-temporal quadrant of the eye (e.g., scarring, thinning, mass) that may affect the implantation, subsequent tissue coverage, and refill-exchange procedure of the PD implant
  • Prior treatment with any medication for geographic atrophy (GA) during the last 3 months prior to screening
  • Prior treatment with any anti-VEGF-C or anti-VEGF-D inhibitors

Exclusion Criteria for Fellow Eye

  • BCVA letter score using ETDRS charts of \< 34 letters
  • Treatment with IVT anti-VEGF or anti-VEGF/Ang-2 agents within one week prior to Day 1 (concurrent treatment with SUSVIMO\^TM in the fellow eye is not exclusionary)

Exclusion Criteria for Either Eye

  • CNV due to causes other than nAMD, such as ocular histoplasmosis, trauma, pathological myopia, angioid streaks, choroidal rupture, uveitis or central serous chorioretinopathy
  • Prior participation in a clinical trial involving anti-VEGF drugs within six months prior to the screening visit, other than ranibizumab, aflibercept, or faricimab including approved biosimilars
  • Active intraocular inflammation (grade trace or above), infectious conjunctivitis, keratitis, scleritis, or endophthalmitis
  • History of uveitis, including history of any intraocular inflammation following intravitreal therapy
  • Prior treatment with brolucizumab
  • Prior gene therapy for nAMD
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
177 participants (actual)

Study arms

  • Experimental
    Part 1: IVT Injections

    Zifibancimig administered in multiple ascending dose levels through IVT injections.

    Drug: Zifibancimig

  • Experimental
    Part 2: PD With High Dose

    Zifibancimig administered at a high dose through the PD implant, followed by ranibizumab, 100 milligrams per milliliter (mg/mL), administered through the PD implant.

    Drug: Zifibancimig · Drug: Ranibizumab · Device: Port Delivery Platform

  • Experimental
    Part 2: PD With Low Dose

    Zifibancimig administered at a low dose through the PD implant, followed by ranibizumab, 100 mg/mL, administered through the PD implant.

    Drug: Zifibancimig · Drug: Ranibizumab · Device: Port Delivery Platform

  • Experimental
    Part 3: PD With High Dose

    Zifibancimig administered at a high dose through the PD implant, followed by ranibizumab, 100 mg/mL, administered through PD implant.

    Drug: Zifibancimig · Drug: Ranibizumab · Device: Port Delivery Platform

  • Experimental
    Part 3: PD With Low Dose

    Zifibancimig administered at a low dose through the PD implant, followed by ranibizumab, 100 mg/mL, administered through PD implant.

    Drug: Zifibancimig · Drug: Ranibizumab · Device: Port Delivery Platform

  • Active comparator
    Part 3: PD With Ranibizumab

    100 mg/mL of ranibizumab administered through the PD implant.

    Drug: Ranibizumab

Interventions

  • DrugZifibancimig

    Part 1: multiple ascending doses by IVT injection. Each participant will receive zifibancimig at a constant volume of 50 microliter (µL) in the study eye. Part 2: participants will be randomized to one of two dose levels of zifibancimig in the PD implant. Part 3: Participants will receive one of the two dose levels of zifibancimig in the PD implant.

    Also known as: RO7250284

  • Participants will receive ranibizumab 100 mg/mL through the PD implant

  • DevicePort Delivery Platform

    Participants will receive intraocular refillable device that is surgically inserted into the eye for continuous delivery of drugs into the vitreous.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Ocular and Systemic (Non-ocular) Adverse Events (AEs)

    Time frame: Part 1: Baseline up to Week 24; Parts 2 & 3: Baseline up to Week 48

  2. Percentage of Participants With Ocular AEs During the Post-operative and Follow-up Periods

    Time frame: Parts 2 and 3: From Day 1 to Week 4 and during follow-up period (up to Week 48)

  3. Percentage of Participants With Adverse Events of Special Interest (AESIs) Including Ocular AESIs

    Time frame: Part 1: Baseline up to Week 24; Parts 2 and 3: Baseline up to Week 48

  4. Percentage of Participants With Ocular AESIs During the Post-operative and Follow-up Periods

    Time frame: Parts 2 and 3: From Day 1 to Week 4 and during follow-up period (up to Week 48)

  5. Duration of Ocular AESIs

    Time frame: Part 1: Baseline up to Week 24; Parts 2 and 3: Baseline up to Week 48

  6. Duration of Ocular AESIs During the Post-operative and Follow-up Periods

    Time frame: Parts 2 and 3: From Day 1 to Week 4 and during follow-up period (up to Week 48)

  7. Percentage of Participants With Adverse Device Effects (ADEs)

    Time frame: Parts 2 and 3: Baseline up to Week 48

  8. Duration of ADEs

    Time frame: Parts 2 and 3: Baseline up to Week 48

  9. Percentage of Participants With Anticipated Serious ADEs (ASADEs)

    Time frame: Parts 2 and 3: Baseline up to Week 48

  10. Duration of ASADEs

    Time frame: Parts 2 and 3: Baseline up to Week 48

  11. Change From Baseline in Early Treatment Diabetic Retinopathy Study - Best Corrected Visual Acuity (ETDRS-BCVA) Score at Week 48

    ETDRS-BCVA will be used to quantify visual acuity. BCVA is measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.

    Time frame: Part 3: Baseline (baseline visit, before implant insertion), and Week 48

Secondary outcomes

  1. Maximum Observed Concentration (Cmax) of Zifibancimig in Blood and Aqueous Humor (AH)

    Time frame: Part 1: Baseline up to Week 24; Parts 2 and 3: Baseline up to Week 144

  2. Time of Maximum Concentration Observed (Tmax) of Zifibancimig in Blood and AH

    Time frame: Part 1: Baseline up to Week 24; Parts 2 and 3: Baseline up to Week 144

  3. Concentration at the End of a Dosing Interval Before the Next Dose Administration (Ctrough) of Zifibancimig in Blood and AH

    Time frame: Part 1: Baseline up to Week 24; Parts 2 and 3: Baseline up to Week 144

  4. Area Under the Curve (AUC) of Zifibancimig in Blood and AH

    Time frame: Part 1: Baseline up to Week 24; Parts 2 and 3: Baseline up to Week 144

  5. Percentage of Participants Who did not Meet Supplemental Treatment Criteria for the PD Implant With Zifibancimig

    Time frame: Part 3: Week 36, Week 40, and Week 44

  6. Percentage of Participants Who Gained or Lost ≥15, ≥10 ≥5 or ≥0 Letters in ETDRS-BCVA Score From Baseline to Week 48

    ETDRS-BCVA will be used to quantify visual acuity. BCVA is measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.

    Time frame: Part 3: Baseline to Week 48

  7. Change From Baseline in Central Subfield Thickness (CST) at Week 48

    Time frame: Part 3: Baseline, and Week 48

  8. Change From Baseline Over Time in CST

    Time frame: Part 3: Baseline to end of follow-up period (up to Week 144)

07

Study locations

37 sites
  • Barnet Dulaney Perkins Eye Center
    Mesa, Arizona 85206, United States
  • Associated Retina Consultants
    Phoenix, Arizona 85020, United States
  • The Retina Partners
    Encino, California 91436, United States
  • Retinal Consultants Med Group
    Sacramento, California 95841, United States
  • Orange County Retina Med Group
    Santa Ana, California 92705, United States
  • Southwest Retina Consultants
    Durango, Colorado 81303, United States
  • Retina Vitreous Assoc of FL
    St. Petersburg, Florida 33711, United States
  • Southern Vitreoretinal Assoc
    Tallahassee, Florida 32308, United States
  • Southeast Retina Center
    Augusta, Georgia 30909, United States
  • University Retina and Macula Associates, PC
    Oak Forest, Illinois 60452, United States
  • Maine Eye Center
    Portland, Maine 04101, United States
  • Johns Hopkins Med
    Baltimore, Maryland 21287, United States
  • Retina Group of Washington
    Chevy Chase, Maryland 20815, United States
  • Cumberland Valley Retina Consultants
    Hagerstown, Maryland 21740, United States
  • Foundation for Vision Research
    Grand Rapids, Michigan 49546, United States
  • Associated Retinal Consultants
    Royal Oak, Michigan 48073, United States
  • VitreoRetinal Surgery, PLLC.
    Saint Louis Park, Minnesota 55416, United States
  • The Retina Institute
    St Louis, Missouri 63128, United States
  • Sierra Eye Associates
    Reno, Nevada 89502, United States
  • Envision Ocular, LLC
    Bloomfield, New Jersey 07003, United States
  • Retina Vit Surgeons/Central NY
    Liverpool, New York 13088, United States
  • Duke Eye Center
    Durham, North Carolina 27705, United States
  • Graystone Eye
    Hickory, North Carolina 28602, United States
  • OSU Eye Physicians & Surgeons
    Columbus, Ohio 43212, United States
  • Mid Atlantic Retina - Wills Eye Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Carolina Eyecare Physicians
    Mt. Pleasant, South Carolina 29464, United States
  • Charles Retina Institute
    Germantown, Tennessee 38138, United States
  • Southeastern Retina Associates
    Knoxville, Tennessee 37922, United States
  • Tennessee Retina PC.
    Nashville, Tennessee 37203, United States
  • Austin Research Center for Retina
    Austin, Texas 78705, United States
  • Austin Clinical Research LLC
    Austin, Texas 78750, United States
  • Retina Consultants of Texas
    Bellaire, Texas 77401, United States
  • Retina Consultants of Texas
    Houston, Texas 77030, United States
  • Retina Center of Texas
    Southlake, Texas 76092, United States
  • Piedmont Eye Center
    Lynchburg, Virginia 24502, United States
  • Spokane Eye Clinical Research
    Spokane, Washington 99204, United States
  • Emanuelli Research and Development Center LLC
    Arecibo, 00612, Puerto Rico
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Aug 2026, 69 months.

Of 52 phase 1/2 interventional studies under Macular Degeneration, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's 69 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2020
First posted
Sep 28, 2020
StartActual
Oct 28, 2020
Primary completionActual
Aug 25, 2026
CompletionActual
Aug 25, 2026
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04567303
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 28, 2020
Start date
Oct 28, 2020
Primary completion
Aug 25, 2026
Completion
Aug 25, 2026
Last update
Sep 14, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion